Similarly, Edasalonexent, a dual NF‐κB inhibitor, was well tolerated and showed a trend toward slowing disease progression in younger paediatric DMD patients, although it did not meet its primary efficacy endpoints and further development was discontinued [ 115 ].
← all excerpts
Downstream Pathways of Dystrophin Deficiency in Duchenne Muscular Dystrophy: Implications for Muscle Degeneration and Regeneration.
1
—
—